IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Core Viewpoint - IceCure Medical Ltd. announced preliminary financial results for the three and six months ended June 30, 2025, highlighting a decrease in product sales compared to the previous year due to shipment delays and fluctuations in customer orders [1][4]. Financial Performance - The company expects product sales of approximately $525,000 for the three months ended June 30, 2025 [2]. - For the six months ended June 30, 2025, product sales were approximately $1.25 million, a decrease from $1.65 million during the same period in 2024 [4]. - The previous year's sales figure excludes $100,000 from an exclusive distribution agreement with Terumo in Japan [4]. Shipment and Order Flow - Order flow was not impacted by the conflict between Israel and Iran, although some non-U.S. customer shipments were temporarily delayed [2]. - More than $200,000 of product sales from delayed shipments are expected to be recognized in July 2025 [2][3]. - The U.S. market was not affected by shipment delays due to sufficient inventory of ProSense® systems and probes [3]. Future Reporting - IceCure plans to report comprehensive financial results for the second quarter and first half of 2025 in August 2025 [5]. - The company does not intend to issue preliminary financial results on a quarterly basis unless warranted [5]. Company Overview - IceCure Medical develops minimally-invasive cryoablation technology for tumor destruction, focusing on breast, kidney, bone, and lung cancer [7]. - The flagship ProSense® system is marketed globally and serves as a safe alternative to surgical tumor removal [7].